Last reviewed · How we verify
GP+CCRT
GP+CCRT is a combination treatment regimen pairing gemcitabine/cisplatin chemotherapy with concurrent chemoradiotherapy to enhance tumor control through synergistic cytotoxic and radiation effects.
GP+CCRT is a combination treatment regimen pairing gemcitabine/cisplatin chemotherapy with concurrent chemoradiotherapy to enhance tumor control through synergistic cytotoxic and radiation effects. Used for Locally advanced solid tumors (specific indication under investigation in phase 3 trial).
At a glance
| Generic name | GP+CCRT |
|---|---|
| Also known as | Experimental group |
| Sponsor | Guiyang Medical University |
| Drug class | Combination chemotherapy with concurrent chemoradiotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This regimen combines gemcitabine and cisplatin chemotherapy agents with concurrent administration of chemotherapy during radiotherapy (CCRT). The chemotherapy drugs induce DNA damage and cell death, while concurrent radiation amplifies cytotoxic effects through radiosensitization. This multimodal approach is designed to improve local and systemic tumor control in solid malignancies.
Approved indications
- Locally advanced solid tumors (specific indication under investigation in phase 3 trial)
Common side effects
- Hematologic toxicity (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Nephrotoxicity
- Radiation dermatitis
Key clinical trials
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC (PHASE2)
- GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma (PHASE2)
- Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE2)
- TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma (PHASE2)
- GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP+CCRT CI brief — competitive landscape report
- GP+CCRT updates RSS · CI watch RSS
- Guiyang Medical University portfolio CI